Science Explorer Back to mapMap
Discussion
Researcher · Springer Nature (New Zealand) · New Zealand

Sohita Dhillon

Sohita Dhillon publishes mostly in Oncology, Molecular Biology and Hematology, on topics such as Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research and Colorectal Cancer Treatments and Studies.

OpenAlex
World rank
#48,969
of 7,710,434 ranked researchers
Rank in New Zealand
#133
of 21,128
Works
191
Citations
9.9k
Citations per work
51.8
h-index
59
i10-index 137Top 2.4% in Oncology
Sohita Dhillon

What does Sohita Dhillon research?

Sohita Dhillon's work is mostly in Medicine (36%), Biochemistry, Genetics and Molecular Biology (8%).

Everything else: 107 works · 55.8% of their workHealth Sciences: 69 works · 36.3% of their workMedicine: 69 works · 36.3% of their workOncology: 25 works · 13.1% of their workHematology: 14 works · 7.3% of their workPulmonary and Respiratory Medicine: 13 works · 6.9% of their workSurgery: 9 works · 4.6% of their workEpidemiology: 8 works · 4.4% of their workLife Sciences: 15 works · 7.9% of their workBiochemistry, Genetics and Molecular Biology: 15 works · 7.9% of their workMolecular Biology: 15 works · 7.9% of their workTHEIR WORKSohita Dhillon191works
Life Sciences8%Health Sciences36%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else10755.8%
    1. Medicine6936.3%
    1. Biochemistry, Genetics and Molecular Biology157.9%
  1. 1Oncology13% of their works
  2. 2Molecular Biology8% of their works
  3. 3Hematology7% of their works
  4. 4Pulmonary and Respiratory Medicine7% of their works
  5. 5Surgery5% of their works
  6. 6Epidemiology4% of their works

Research topics

Which keywords describe Sohita Dhillon's research?

The keywords of their largest research topics: Chemotherapy, Clinical Trials, Targeted Therapy, Prognostic Factors, Rituximab, Epidemiology, ALK Inhibitors and EGFR Mutations.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 22 words, with their numbers
  1. Chemotherapy283 topics
  2. Clinical Trials222 topics
  3. Targeted Therapy222 topics
  4. Prognostic Factors202 topics
  5. Rituximab202 topics
  6. Epidemiology162 topics
  7. ALK Inhibitors141 topic
  8. EGFR Mutations141 topic
  9. Cetuximab121 topic
  10. Chronic Lymphocytic Leukemia121 topic
  11. Genomic Aberrations121 topic
  12. KRAS Mutations121 topic
  13. Bacterial Meningitis81 topic
  14. Breast Cancer81 topic
  15. Classification81 topic
  16. Community-Acquired Pneumonia81 topic
  17. Genomic Profiles81 topic
  18. HER281 topic
  19. Lymphoma81 topic
  20. Neisseria meningitidis81 topic
  21. Pneumococcal Conjugate Vaccine81 topic
  22. Small-Cell Lung Cancer81 topic

Where does Sohita Dhillon work?

Sohita Dhillon's main affiliation in the publication record is Springer Nature (New Zealand), New Zealand.

How many publications and citations does Sohita Dhillon have?

OpenAlex counts 191 works and 9,890 citations for Sohita Dhillon, an h-index of 59, ranking #48,969 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Sohita Dhillon. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.